Clinical Trial Update: FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a new phosphate binder for reducing FGF23 in chronic kidney disease; trial status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• New Phosphate Binder

Snippet

Sponsor: Centre Hospitalier Universitaire, Amiens | Conditions: Chronic Renal Failure | Phase 3 | Status: COMPLETED